PE20050222A1 - Compuestos de triazol como antagonistas de vasopresina - Google Patents

Compuestos de triazol como antagonistas de vasopresina

Info

Publication number
PE20050222A1
PE20050222A1 PE2004000165A PE2004000165A PE20050222A1 PE 20050222 A1 PE20050222 A1 PE 20050222A1 PE 2004000165 A PE2004000165 A PE 2004000165A PE 2004000165 A PE2004000165 A PE 2004000165A PE 20050222 A1 PE20050222 A1 PE 20050222A1
Authority
PE
Peru
Prior art keywords
alkyl
tetraaza
benzo
chloro
ring
Prior art date
Application number
PE2004000165A
Other languages
English (en)
Inventor
Justin Stephen Bryans
Patrick Stephen Johnson
Alan Stobie
Thomas Ryckmans
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20050222A1 publication Critical patent/PE20050222A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A DERIVADOS DE TRIAZOL DE FORMULA (I), DONDE V ES -(CH2)d(O)e-, -CO-, O -CH(ALQUILOC1-C6); W ES -O-, -S(O)a- O -N(R1)-; R1 ES H, ALQUILO(C1-C6), (CH2)bCOR2, CO(CH2)bNR2R3, SO2R2, (CH2)cOR2, (CH2)cNR2R3 O (CH2)bhet1; het1 ES UN HETEROCICLO DE 3 A 8 ATOMOS QUE PUEDE CONTENER O, N O S, OPCIONALMENTE SUSTITUIDOS CON ALQUILO(C1-C6); X E Y SON H, ALQUILO(C1-C6), HALOGENO, OH, CF3, OCF3, OR4; Z ES -(CH2)f(O)g-, -CO-, O -CH(ALQUILO(C1-C6))-; EL ANILLO A ES UN HETEROCICLO SATURADO QUE CONTIENE N, DE 4 A 7 MIEMBROS OPCIONALMENTE SUSTITUIDO CON OH Y AL MENOS UN N DEL ANILLO PUEDE ESTAR SUSTITUIDO CON O; EL ANILLO B ES UN FENILO O UN HETEROCICLO INSATURADO QUE CONTIENE N, DE 4 A 7 MIEMBROS, OPCIONALMENTE SUSTITUIDO CON OH, HALOGENO, CN, CONH2, CF3, OCF3, Y AL MENOS UN N PUEDE ESTAR SUSTITUIDO CON O. SON COMPUESTOS PREFERIDOS: TRICLOROHIDRATO DE 8-CLORO-5-METIL-1-(3,4,5,6-TETRAHIDRO-2H-[1,2']BIPIRIDINIL-4-IL)-5,6-DIHIDRO-4H-2,3,5,10b-TETRAAZA-BENZO[e]AZULENO, 8-CLORO-5-METANOSULFONIL-1-(3,4,5,6-TETRAHIDRO-2H-[1,2']-BIPIRIDINIL-4-IL)-5,6-DIHIDRO-4H-2,3,5,10b-TETRAAZA-BENZO[e]AZULENO, DIMETILAMINO DEL ACIDO 8-CLORO-1-(1-PIRIMIDIN-2-IL-PIPERIDIN-4-IL)-4H,6H-2,3,5,10b-TETRAAZA-BENZO[e]AZULENO-5-SULFONICO, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE ELABORACION Y COMPUESTOS INTERMEDIOS. UNA FORMULACION FARMACEUTICA QUE LOS CONTIENE. ESTOS COMPUESTOS MUESTRAN UNA ACTIVIDAD ANTAGONISTA DE VASOPRESINA Y PUEDEN USARSE EN EL TRATAMIENTO DE DISMENORREA
PE2004000165A 2003-02-19 2004-02-17 Compuestos de triazol como antagonistas de vasopresina PE20050222A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0303852.8A GB0303852D0 (en) 2003-02-19 2003-02-19 Triazole compounds useful in therapy

Publications (1)

Publication Number Publication Date
PE20050222A1 true PE20050222A1 (es) 2005-04-13

Family

ID=9953327

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000165A PE20050222A1 (es) 2003-02-19 2004-02-17 Compuestos de triazol como antagonistas de vasopresina

Country Status (11)

Country Link
CN (1) CN1751047A (es)
AR (1) AR043210A1 (es)
CL (1) CL2004000293A1 (es)
GB (1) GB0303852D0 (es)
GT (1) GT200400020A (es)
NL (1) NL1025527C2 (es)
PA (1) PA8596101A1 (es)
PE (1) PE20050222A1 (es)
TW (1) TW200500367A (es)
UY (1) UY28201A1 (es)
WO (1) WO2004074291A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0325021D0 (en) * 2003-10-27 2003-12-03 Pfizer Ltd Therapeutic combinations
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
DE102004001871A1 (de) * 2004-01-14 2005-09-01 Bayer Healthcare Ag Tricyclische Benzazepin-Derivate und ihre Verwendung
MX2007002248A (es) 2004-08-25 2008-10-02 Pfizer Triazolobenzodiazepinas y su uso como antagonistas de vasopresina.
CA2605899C (en) * 2005-04-26 2011-02-08 Pfizer Limited Triazole derivatives as vasopressin antagonists
AU2009315754B2 (en) 2008-11-13 2013-08-15 F. Hoffmann-La Roche Ag Spiro-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulenes
EP2358714B1 (en) * 2008-11-18 2012-08-01 F. Hoffmann-La Roche AG Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
MX2011005596A (es) 2008-11-28 2011-06-16 Hoffmann La Roche Arilciclohexileteres de dihidro-tetraazabenzoazulenos para uso como antagonistas del receptor de vasopresina via.
CA2756871A1 (en) 2009-03-31 2010-10-07 Arqule, Inc. Substituted heterocyclic compounds
WO2011058193A1 (en) * 2009-11-16 2011-05-19 Mellitech [1,5]-diazocin derivatives
US8420633B2 (en) * 2010-03-31 2013-04-16 Hoffmann-La Roche Inc. Aryl-cyclohexyl-tetraazabenzo[e]azulenes
US8461151B2 (en) * 2010-04-13 2013-06-11 Hoffmann-La Roche Inc. Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes
US8492376B2 (en) 2010-04-21 2013-07-23 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes
US8481528B2 (en) * 2010-04-26 2013-07-09 Hoffmann-La Roche Inc. Heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes
US8513238B2 (en) * 2010-05-10 2013-08-20 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes
US9006450B2 (en) * 2010-07-01 2015-04-14 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
BR112013008420A2 (pt) 2010-10-07 2016-06-28 Takeda Pharmaceutical composto, medicamento, e, uso do composito
RU2011122942A (ru) 2011-06-08 2012-12-20 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Новые ингибиторы киназ
US8828989B2 (en) * 2011-09-26 2014-09-09 Hoffmann-La Roche Inc. Oxy-cyclohexyl-4H,6H-5-oxa-2,3,10b-triaza-benzo[E]azulenes as V1A antagonists
MX2014003600A (es) * 2011-10-05 2014-04-25 Hoffmann La Roche Ciclohexil-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenos como antagonistas v1a.
CN104364239B (zh) 2012-06-13 2017-08-25 霍夫曼-拉罗奇有限公司 二氮杂螺环烷烃和氮杂螺环烷烃
CN102766674A (zh) * 2012-07-25 2012-11-07 辉源生物科技（上海）有限公司 食蟹猴抗利尿激素受体v1a拮抗剂筛选平台的建立
AR092645A1 (es) 2012-09-25 2015-04-29 Hoffmann La Roche Derivados biciclicos inhibidores de autotaxina (atx)
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
CN105492010B (zh) 2013-08-19 2020-01-03 豪夫迈·罗氏有限公司 用于治疗相移睡眠障碍的V1a拮抗剂
CN105764905B (zh) 2013-11-26 2019-06-07 豪夫迈·罗氏有限公司 新的八氢-环丁二烯并[1，2-c；3，4-c’]二吡咯-2基
MY175464A (en) 2013-12-05 2020-06-29 Hoffmann La Roche Synthesis of trans-8-chloro-5-methyl-1-[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulene and crytalline forms thereof
PL3122750T3 (pl) 2014-03-26 2020-03-31 F.Hoffmann-La Roche Ag Związki bicykliczne jako inhibitory wytwarzania autotaksyny (ATX) i kwasu lizofosfatydowego (LPA)
EA032357B1 (ru) 2014-03-26 2019-05-31 Ф. Хоффманн-Ля Рош Аг Конденсированные [1,4]диазепиновые соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
MX2018000511A (es) 2015-09-04 2018-04-24 Hoffmann La Roche Derivados de fenoximetilo.
MA42923A (fr) 2015-09-24 2021-04-28 Hoffmann La Roche Composés bicycliques comme inhibiteurs mixtes de atx/ca
EP3353180B1 (en) 2015-09-24 2022-03-16 F. Hoffmann-La Roche AG Bicyclic compounds as atx inhibitors
CR20180143A (es) 2015-09-24 2018-05-03 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores duales de atx/ca
AU2016328437A1 (en) 2015-09-24 2018-01-25 F. Hoffmann-La Roche Ag Bicyclic compounds as ATX inhibitors
CA3053329A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag Heterocyclic compounds useful as dual atx/ca inhibitors
JP7090099B2 (ja) 2017-03-16 2022-06-23 エフ．ホフマン－ラ ロシュ アーゲー Ａｔｘインヒビターとしての新規二環式化合物
US11186577B2 (en) * 2017-06-05 2021-11-30 Blackthorn Therapeutics, Inc. Vasopressin receptor antagonists and products and methods related thereto
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物
CN111170983B (zh) * 2019-12-26 2021-07-09 中国农业大学 一种苄硫基乙酰胺类化合物及其制备方法与应用
TWI804119B (zh) * 2020-12-21 2023-06-01 大陸商上海濟煜醫藥科技有限公司 三氮唑類三并環衍生物及其製備方法和應用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823475D0 (en) * 1988-10-06 1988-11-16 Merck Sharp & Dohme Chemical compounds
US5438035A (en) * 1994-06-24 1995-08-01 American Cyanamid Company Methods for controlling undesirable plant species with benzodiazepine compounds
US5753648A (en) * 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
HUP9904514A3 (en) * 1996-11-01 2000-10-30 Wyeth Corp 5h-pyrrolo[2,1-c][1,4]-benzodiazepin 3-carboxamide derivatives, process for their preparation, their use and pharmaceutical compositions containing them
PL205704B1 (pl) * 1999-01-19 2010-05-31 Ortho Mcneil Pharm Inc Związki tricyklicznej benzodiazepiny, kompozycja farmaceutyczna zawierająca te związki oraz ich zastosowanie
US7109193B2 (en) * 2001-04-12 2006-09-19 Wyeth Tricyclic diazepines tocolytic oxytocin receptor antagonists

Also Published As

Publication number Publication date
GT200400020A (es) 2004-09-21
PA8596101A1 (es) 2005-08-04
CL2004000293A1 (es) 2005-01-07
NL1025527C2 (nl) 2005-03-14
TW200500367A (en) 2005-01-01
GB0303852D0 (en) 2003-03-26
AR043210A1 (es) 2005-07-20
UY28201A1 (es) 2004-09-30
NL1025527A1 (nl) 2004-08-23
CN1751047A (zh) 2006-03-22
WO2004074291A1 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
PE20050222A1 (es) Compuestos de triazol como antagonistas de vasopresina
AR022230A1 (es) Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para preparar dicha composicion
TR200400541T4 (tr) Terapide faydalı tropan türevleri.
ATE380818T1 (de) Piperazine-substituierte aryl-benzodiazepinen und ihre verwendung als dopaminrezeptor-antagonisten zur behandlung von psychose
EA200201179A1 (ru) Производные 2-аминокарбонил-9h-пурина
EA200400054A1 (ru) Замещенные нафтилиндольные производные в качестве ингибиторов ингибитора активатора плазминогена типа 1 (pai-1)
ATE365740T1 (de) Substituierte pyrazolopyrimidine
PE20070018A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
CY1110382T1 (el) Πυραζινο υποκατεστημενες αρυλοβενζοδιαζεπινες
PE20080706A1 (es) Arilmidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
NZ509321A (en) Use of an estrogen agonist/antagonist to treat conditions responsive to estrogen such as rheumatoid arthritis, colon cancer, tissue wounds and cataracts
EA200301306A1 (ru) Производные 1-фенилсульфонил-1,3-дигидро-2h-индол-2-она, их получение и их терапевтическое применение
UY27109A1 (es) Derivados de quinazolona como antagonistas de receptores adrenergicos alfa-1a/b
PA8547901A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
MXPA05011710A (es) Derivados de pirimidina con actividad de crf.
UY24472A1 (es) Composiciones de agonistas/antagonistas de estrógenos y agonistas/antagonistas de prostaglandinas, útiles en el tratamiento de la osteoporosis
ITRM20010356A1 (it) "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
PA8495101A1 (es) Derivados de 13-metileritromicina
AR050084A1 (es) Derivados de bencimidazolona como inhibidores de hsp90
AR031379A1 (es) Derivados indoloquinazolin-5-onas, un proceso para su preparacion, composicion farmaceutica y el uso de dichos derivados para la fabricacion de dichos medicamentos
TR200002380T2 (tr) Yeni triazolo (4,5-d) pirimidin bileşikleri
ATE302203T1 (de) Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
EA200500882A1 (ru) N-арилсульфонил-3-аминоалкоксииндолы
TR200101711T2 (tr) Antihistaminik spiro bileşikler.
HUP0105201A2 (hu) Férfiklimax kezelése ösztrogén agonistákat/antagonistákat és tesztoszteront tartalmazó gyógyászati készítmények alkalmazásával

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed